Tag: medicine

U.S. Department of Health and Human Services and The Rockefeller Foundation Partner to Accelerate the Adoption of Food is Medicine in Health Systems

WASHINGTON | January 31, 2024 ― The U.S. Department of Health and Human Services (HHS) and The Rockefeller Foundation announced a new partnership to accelerate the adoption of Food is Medicine in health systems. Through this partnership, HHS and The Rockefeller Foundation aim to improve health outcomes and health equity by engaging a broader public audience in understanding nutrition, accelerating collective understanding of Food is Medicine interventions and their impacts, and exploring strategies to scale successful Food Is Medicine programs to more eligible Americans.

“We know good food is the foundation of good health, and study after study has found Food is Medicine interventions can make people healthier while reducing health care costs,” said Dr. Rajiv J. Shah, President of The Rockefeller Foundation. “I am proud The Rockefeller Foundation will be collaborating with HHS to help improve health outcomes and advance health equity by ensuring Food is Medicine interventions reach those who stand to benefit from them most.”

While Food is Medicine programs are widely recognized as powerful interventions, they only reach a fraction of those who could benefit. Through a public-private partnership, HHS and The Rockefeller Foundation will exchange information and ideas to:

  • Advance and leverage research design and findings through knowledge to produce definitive evidence on clinical health outcomes, cost effectiveness, and optimal program design.
  • Engage a broader public audience in the meaning and value of FIM interventions and resources.
  • Support Food is Medicine adoption by identifying opportunities and barriers to support greater uptake and scaling.
  • Ensure Food is Medicine supports diverse individuals and communities with a focus on health equity.

“HHS and The Rockefeller Foundation are working together to accelerate food as medicine adoption in various health systems and communities. We are eager to build on this dynamic opportunity and we anticipate powerful outcomes through collaborative

Israeli patients received wrong medicine in major system failure

An undetermined number of patients across Israeli hospitals received the wrong prescription of medication due to a significant malfunction in the Chameleon software used across the country, the Health Ministry said on Tuesday.

This collapse of the medical software, integral to the operation and treatment processes in emergency rooms and hospital departments across Israel, comes when the healthcare system is already experiencing unprecedented levels of strain. 

The malfunction has resulted in incorrect medications being prescribed to patients, and the full extent of this issue is currently under investigation.

What is the Chameleon software used by Israeli hospitals?

Developed by Elad Systems, the Chameleon software serves as the central computing element in Israeli hospitals. It provides a comprehensive view of all patients in a department or emergency room and their treatment status through a direct overview table. The software features color-coded sections to identify laboratory tests, imaging, consultations, discharges, and more. Clicking on a patient’s name gives a detailed screen with their complete medical information.

About 10 days ago, the Health Ministry began receiving initial reports from a hospital about medication record errors for some patients. Specifically, the discharge letters of these patients contained incorrect prescriptions. Following an influx of similar reports, the Ministry initiated an extensive investigation. Hospitals have been directed to verify the accuracy of medications for each patient.

A doctor using the Chameleon system (illustrative) (credit: MAARIV)

The Ministry estimates that the issue affects at least dozens of patients, though it’s still unclear whether the errors occurred during hospitalization or in the discharge medication recommendations. No other management errors, such as those in laboratory tests or imaging, have been identified. The software company has temporarily fixed the malfunction, but the affected patients remain unidentified. An investigation is ongoing to determine if this was a cyber-related event.


13 Things To Know About Paxlovid, the Latest COVID-19 Pill > News > Yale Medicine

[Originally published: March 10, 2022. Updated: Jan. 10, 2024]

Note: Information in this article was accurate at the time of original publication. Because information about COVID-19 changes rapidly, we encourage you to visit the websites of the Centers for Disease Control & Prevention (CDC), World Health Organization (WHO), and your state and local government for the latest information.

Paxlovid, the pill that has become the go-to treatment for COVID-19 treatment, was granted full approval in May by the Food and Drug Administration (FDA) for the treatment of mild-to-moderate COVID-19 in adults at high risk for severe disease, including hospitalization and death. The drug also remains available to everyone 12 and older (weighing at least 88 pounds) who has mild-to-moderate disease and is at high risk for severe disease under an FDA Emergency Use Authorization.

Paxlovid is an oral antiviral pill that can be taken at home to help keep high-risk patients from getting so sick that they need to be hospitalized. So, if you are eligible to take the pills, you can take them at home and lower your risk of going to the hospital.

The drug, developed by Pfizer, had an 89% reduction in the risk of hospitalization and death in unvaccinated people in the clinical trial that supported the EUA, a number that was high enough to prompt the National Institutes of Health (NIH) to prioritize it over other COVID-19 treatments. Studies outside of the laboratory have since confirmed Paxlovid’s effectiveness among people who have been vaccinated. It’s cheaper than many other COVID-19 drugs (at this time, U.S. residents eligible for Paxlovid will continue to receive the medicine at no charge), and it is expected to work against the latest Omicron subvariants.

“It’s really our first efficacious oral antiviral pill for this virus,” says Scott Roberts, MD, a

A Guide to Safe Use > News > Yale Medicine

Do not use generative AI for advice, such as whether you should go to the emergency room for chest pain, the doctors say.

“Currently, the chatbot cannot create a risk profile on an individual patient at a particular point in time, so it’s better to avoid those types of questions,” says Andrew Taylor, MD, MHS, a Yale Medicine emergency department (ED) physician, who is also leading Yale’s 2024 AI in Medicine Symposium.

Rather, here are some tips for trying generative AI:

1. Use it to provide context or education.

For example, try the prompt: “I was told to take these medications; please explain them to me.” Or “How is [insert condition] diagnosed?”

Generative AI can also explain medical terminology you find on a lab report or imaging results, Dr. Taylor adds. “From a patient education standpoint, AI has the potential to be a great tool,” he says.

2. Know that some AI platforms are not updated in real time.

Although there are reports that some AI platforms have up-to-date information for users with premium—or paid—subscriptions, for others, the data AI relies on to answer questions may not have been updated for a few years.

Because medical information is always changing, that lag in data may mean that the AI responses are not capturing the latest medical knowledge on conditions or treatments.

3. Consider the source.

One of the advantages of doing a standard search through Google is transparency, Dr. Wilson explains. “If I see that the top link [in the search results] is from a trusted source, such as the American Medical Association, I can be sure they vetted it and that the information will be accurate,” he says. “But if I use generative AI, it might not tell me where the information is coming from.”

4. Maintain some

Announcement: Dr. David A. Steven re-appointed chair Department of Clinical Neurological Sciences – Schulich School of Medicine & Dentistry


We are pleased to announce that Dr. David A. Steven has been re-appointed to the Department of Clinical Neurological Sciences as:

• Chair (Schulich School of Medicine & Dentistry, Western University);
• Physician Department Executive (London Health Sciences Centre); and
• Chief (St. Joseph’s Health Care London).

The re-appointment will be effective January 1, 2024, to December 31, 2028.

Dr. Steven earned his Bachelor of Science in 1992 and MD in 1996 from the University of Manitoba. He then went on to complete his residency in neurosurgery at the Schulich School of Medicine and Dentistry at Western University in 2002, followed by a fellowship in epilepsy surgery at the Montréal Neurological Institute. Dr. Steven also obtained his Masters of Public Health from Yale University during his residency.

Dr. Steven joined the Department of Clinical Neurological Sciences at Schulich Medicine & Dentistry in 2003, where he is currently a Professor. He holds a cross-appointment in the Department of Epidemiology and Biostatistics. Dr. Steven holds the Richard Ivey Chair in Clinical Neurological Sciences as the Chair of the Department. He will be renewed in the Endowed Chair through his term as the Chair.

Dr. Steven is also a neurosurgeon at LHSC and an Associate Scientist at Lawson Health Research Institute.

Dr. Steven is dedicated to residency and fellowship education. He has served as Director of the neurosurgery residency program and directs the epilepsy surgery fellowship at Schulich Medicine and Dentistry at Western University. The residency program is one-of-its-kind premiere fellowship in Canada, with fellows from all over the world being trained in London.

Nationally, Dr. Steven is closely associated with the Royal College of Physicians and Surgeons of Canada, serving as a member of the Specialty Committee in Neurosurgery, as well as a Royal College surveyor and examiner. He has been an

Opinion | What cautious adoption of AI in medicine looks like

You’re reading The Checkup With Dr. Wen, a newsletter on how to navigate covid-19 and other public health challenges. Click here to get the full newsletter in your inbox, including answers to reader questions and a summary of new scientific research.

Many readers wrote in the past week to express their worries about the artificial intelligence revolution in health care in response to my recent column on the topic. “My doctor already spends the entire visit with eyes glued to a computer,” Tom from Vermont wrote. “I don’t want the next step to be the computer doing the talking.”

“Call me old-fashioned, but no thanks,” wrote Jennifer from Virginia. “I prefer human interactions to a robot doctor.”

I empathize with concerns that some technological advances might get in the way of the patient-doctor relationship, though I think Tom’s and Jennifer’s scenarios are unlikely to materialize any time soon. Medicine is a conservative profession that’s slow to adopt change, and health-care providers are generally taking a cautious approach to AI.

Many of the current AI uses are quite banal. Adam Landman, an emergency physician and chief information officer for Mass General Brigham in Boston, gave me several examples of how his hospitals have incorporated AI technology to reduce inefficiencies.

One is in the development of staff training videos. In the past, they would hire actors to read a script. If the script needed editing, they’d have to bring back the actors. They’ve now piloted an AI product that allows users to choose an avatar and digitally enter the script. The video is created right away, and edits can be made seamlessly at a fraction of the original cost.

Another is in routing phone calls. Instead of placing

Back To Top